Liang Jian, Deng Xin, Lin Zhi-Xiu, Zhao Li-Chun, Zhang Xi-Liu
The Affiliated Ruikang Hospital of Guangxi Traditional Chinese Medical College, Nanning 530011, Guangxi Zhuang Autonomous Region, China.
World J Gastroenterol. 2009 Sep 28;15(36):4529-37. doi: 10.3748/wjg.15.4529.
To investigate the inhibitory effect of natural taurine (NTau) on portal hypertension (PHT) in rats with experimentally-induced liver cirrhosis (LC).
Experimentally-induced LC Wistar rats (20 rats/group) were treated with either oral saline or oral NTau for 6 consecutive weeks. Evaluation parameters included portal venous pressure (PVP), portal venous resistance (PVR), portal venous flow (PVF), splanchnic vascular resistance (SVR) and mean arterial pressure (MAP). Vasoactive substance levels including nitric oxide (NO), nitric oxide synthase (NOS) and cyclic guanosine monophosphate (cGMP) were also measured. Histological investigation of type I and III collagen (COL I and III) and transforming growth factor-beta(1) (TGF-beta1) was also performed.
Treatment with NTau (1) significantly decreased PVP, PVR and PVF, and increased MAP and SVP; (2) markedly increased the vascular compliance and reduced the zero-stress of the portal vein; (3) markedly decreased the amount of NO and cGMP and activity of NOS; and (4) improved the pathological status of the liver tissue and reduced the expression of COL I, COL III and TGF-beta1.
NTau inhibited the LC-induced PHT by improving hyperdynamic circulation, morphology of liver and biomechanical properties of the portal vein in experimentally-induced LC rats.
研究天然牛磺酸(NTau)对实验性肝硬化(LC)大鼠门静脉高压(PHT)的抑制作用。
将实验性诱导的LC Wistar大鼠(每组20只)连续6周口服生理盐水或口服NTau进行治疗。评估参数包括门静脉压力(PVP)、门静脉阻力(PVR)、门静脉血流量(PVF)、内脏血管阻力(SVR)和平均动脉压(MAP)。还测量了包括一氧化氮(NO)、一氧化氮合酶(NOS)和环磷酸鸟苷(cGMP)在内的血管活性物质水平。对I型和III型胶原蛋白(COL I和III)以及转化生长因子-β1(TGF-β1)进行了组织学研究。
用NTau治疗(1)显著降低了PVP、PVR和PVF,并增加了MAP和SVP;(2)显著增加了血管顺应性并降低了门静脉的零应力;(3)显著降低了NO和cGMP的量以及NOS的活性;(4)改善了肝组织的病理状态并降低了COL I、COL III和TGF-β1的表达。
NTau通过改善实验性诱导的LC大鼠的高动力循环、肝脏形态和门静脉的生物力学特性来抑制LC诱导的PHT。